Recent Quotes (30 days)

You have no recent quotes
chg | %

Transition Therapeutics Inc  

(Public, TSE:TTH)   Watch this stock  
Find more results for TTH
+0.02 (0.79%)
Oct 9 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 2.52 - 2.55
52 week 2.19 - 11.50
Open 2.52
Vol / Avg. 1,200.00/1,971.00
Mkt cap 99.14M
P/E     -
Div/yield     -
EPS -1.41
Shares 38.88M
Beta 0.85
Inst. own     -
Nov 10, 2015
Q1 2016 Transition Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 15, 2015
Q4 2015 Transition Therapeutics Inc Earnings Call
Sep 15, 2015
Q4 2015 Transition Therapeutics Inc Earnings Release
Aug 13, 2015
Transition Therapeutics Inc at Canaccord Genuity Growth Conference

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -102.45% -86.61%
Return on average equity -129.41% -107.14%
Employees 18 -
CDP Score - -


101 College St Suite 220
+1-416-2607770 (Phone)
+1-416-2602886 (Fax)

Website links


Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing therapeutics for disease indications with markets. The Company’s wholly-owned subsidiary, Transition Therapeutics Ireland Limited is developing CNS drug candidate ELND005 for the treatment of Alzheimer’s disease and Down syndrome. The Company’s technologies in development include ELND005 for the treatment of Alzheimer’s disease, bipolar disorder and Down syndrome, and TT401/402 for the treatment of diabetes. The Company is engaged in developing disease-modifying small molecule therapeutics that act by preventing the formation of and breaking down amyloid beta peptide aggregates. TT-401 provides glycemic control and other effects, including weight loss.

Officers and directors

Tony F. Cruz Ph.D. Chairman of the Board, Chief Executive Officer
Carl Damiani President, Chief Operating Officer
Age: 40
Nicole Rusaw Chief Financial Officer
Age: 39
Bruce Connop Vice President - Non-Clinical & Pharmaceutical Development
Age: 43
Aleksandra Pastrak Vice President - Clinical Development and Medical Officer
Age: 46
Louis Alexopoulos Secretary
Michael Richard Dwyer Ashton Lead Independent Director
Age: 69
Paul Baehr Independent Director
Age: 69
Christopher M. Henley Independent Director
Age: 52
Gary W. Pace Ph.D. Independent Director
Age: 67